验证数据展示
经过测试的应用
| Positive WB detected in | HepG2 cells, Jurkat cells |
| Positive IP detected in | HepG2 cells |
| Positive IHC detected in | human liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:500-1:3000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
17394-1-AP targets AlaRS in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human samples.
| 经测试应用 | WB, IHC, IF/ICC, IP, ELISA Application Description |
| 文献引用应用 | WB, IHC, CoIP |
| 经测试反应性 | human |
| 文献引用反应性 | human |
| 免疫原 | AlaRS fusion protein Ag11294 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | alanyl-tRNA synthetase |
| 别名 | AARS, Renal carcinoma antigen NY-REN-42, EC:6.1.1.7, Alanyl-tRNA synthetase, Alanine--tRNA ligase, cytoplasmic |
| 计算分子量 | 968 aa, 107 kDa |
| 观测分子量 | 107 kDa |
| GenBank蛋白编号 | BC011451 |
| 基因名称 | AlaRS |
| Gene ID (NCBI) | 16 |
| RRID | AB_2219748 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | P49588 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
AARS(alanyl-tRNA synthetase) is also named as AlaRS(alanine tRNA ligase 1, cytoplasmic), renal carcinoma antigen NY-REN-42 and belongs to the class-II aminoacyl-tRNA synthetase family. It can interpret the RNA code and attach specific aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. AARS consists of three domains: the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs(PMID:19661429).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for AlaRS antibody 17394-1-AP | Download protocol |
| IHC protocol for AlaRS antibody 17394-1-AP | Download protocol |
| IF protocol for AlaRS antibody 17394-1-AP | Download protocol |
| IP protocol for AlaRS antibody 17394-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Nat Commun Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes | ||
Cancer Lett K90 lactylation orchestrates YAP nuclear sequestration by impairing binding with exportin CRM1 and enhances HCC malignancy | ||
Sci Adv Infection-induced lysine lactylation enables herpesvirus immune evasion
|
